Across TCGA pan-cancer cohorts, MRTFA Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MRTFA data layer compared with 17 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MRTFA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRTFA expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

UCEC, PRAD, and SKCM are the cancer types where MRTFA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.533	0.755	<.001	8	view →
PRAD	DFS	Median	All	0.136	0.776	<.001	6	view →
SKCM	DFS	Median	All	0.815	0.213	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MRTFA tumor-vs-normal RNA expression · all MRTFA data types